Syngene International Limited announced its financial results for the second quarter of FY26 on November 5, 2025, revealing a 4% sequential and 2% year-on-year increase in revenue from operations, totaling Rs. 911 crore. For the first half of the fiscal year, revenue rose by 6% to Rs. 1,785 crore. Despite this growth in revenue, the company reported a decline in EBITDA, which fell by 18% to Rs. 215 crore, leading to a reduced EBITDA margin of 23.2%. Furthermore, the reported profit after tax (PAT) before exceptional items dropped by 37%, reflecting challenges in certain operational areas.

Managing Director and CEO Peter Bains stated that the quarterly performance was bolstered by growth in research services, which offset inventory corrections in biologics manufacturing. He highlighted the company's achievement of securing its first contract for a global phase III clinical trial from a U.S.-based biotech firm. In addition, Syngene is actively expanding its capabilities with the construction of a GMP bioconjugation suite in Bengaluru, aimed at enhancing its capacity for manufacturing Antibody Drug Conjugates (ADCs). The company remains optimistic about the U.S. biotech funding environment, with early signs of improvement noted.

Chief Financial Officer Deepak Jain emphasized the company's strong balance sheet, which offers the flexibility to invest in strategic priorities and expand facilities for peptides and ADCs. Syngene is also enhancing its global clinical trials footprint with new partnerships in various countries, including Australia and the UK. As part of its sustainability efforts, Syngene achieved the highest level of ‘Green Certification’ for its laboratories, demonstrating its commitment to environmentally responsible practices. An investor call is scheduled for November 6, 2025, to further discuss the company's performance and future outlook.